A Randomized Controlled Trial to Establish Effects of Short-term Rapamycin Treatment in 24 Middle-aged Companion Dogs

Overview

Journal Geroscience

Specialty Geriatrics

Date 2017 Apr 5

PMID 28374166

Citations 100

Authors

Silvan R Urfer

Tammi L Kaeberlein

Susan Mailheau

Philip J Bergman

Kate E Creevy

Daniel E L Promislow

Matt Kaeberlein

Affiliations

Soon will be listed here.

Abstract

Age is the single greatest risk factor for most causes of morbidity and mortality in humans and their companion animals. As opposed to other model organisms used to study aging, dogs share the human environment, are subject to similar risk factors, receive comparable medical care, and develop many of the same age-related diseases humans do. In this study, 24 middle-aged healthy dogs received either placebo or a non-immunosuppressive dose of rapamycin for 10 weeks. All dogs received clinical and hematological exams before, during, and after the trial and echocardiography before and after the trial. Our results showed no clinical side effects in the rapamycin-treated group compared to dogs receiving the placebo. Echocardiography suggested improvement in both diastolic and systolic age-related measures of heart function (E/A ratio, fractional shortening, and ejection fraction) in the rapamycin-treated dogs. Hematological values remained within the normal range for all parameters studied; however, the mean corpuscular volume (MCV) was decreased in rapamycin-treated dogs. Based on these results, we will test rapamycin on a larger dog cohort for a longer period of time in order to validate its effects on cardiac function and to determine whether it can significantly improve healthspan and reduce mortality in companion dogs.

Citing Articles

Roadmap for alleviating the manifestations of ageing in the cardiovascular system.

Liberale L, Tual-Chalot S, Sedej S, Ministrini S, Georgiopoulos G, Grunewald M Nat Rev Cardiol. 2025; .

PMID: 39972009 DOI: 10.1038/s41569-025-01130-5.

Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.

Coleman A, Creevy K, Anderson R, Reed M, Fajt V, Aicher K Geroscience. 2025; .

PMID: 39951177 DOI: 10.1007/s11357-024-01484-7.

The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals.

Harinath G, Lee V, Nyquist A, Moel M, Wouters M, Hagemeier J Geroscience. 2025; .

PMID: 39873920 DOI: 10.1007/s11357-025-01532-w.

Involvement of TGF-β, mTOR, and inflammatory mediators in aging alterations during myxomatous mitral valve disease in a canine model.

Grzeczka A, Graczyk S, Kordowitzki P Geroscience. 2025; .

PMID: 39865135 DOI: 10.1007/s11357-025-01520-0.

Mikhail 'Misha' Blagosklonny's enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.

Barzilai D Aging (Albany NY). 2025; 17(1):1-15.

PMID: 39808121 PMC: 11810056. DOI: 10.18632/aging.206189.

References

Yi H, Brooks E, Thurberg B, Fyfe J, Kishnani P, Sun B . Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med (Berl). 2014; 92(6):641-50. DOI: 10.1007/s00109-014-1127-4. View

Gamaldo A, Ferrucci L, Rifkind J, Longo D, Zonderman A . Relationship between mean corpuscular volume and cognitive performance in older adults. J Am Geriatr Soc. 2013; 61(1):84-9. PMC: 3555566. DOI: 10.1111/jgs.12066. View

Edinger A, Linardic C, Chiang G, Thompson C, Abraham R . Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 2003; 63(23):8451-60. View

Neff F, Flores-Dominguez D, Ryan D, Horsch M, Schroder S, Adler T . Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013; 123(8):3272-91. PMC: 3726163. DOI: 10.1172/JCI67674. View

Xu B, Daimon M . Cardiac aging phenomenon and its clinical features by echocardiography. J Echocardiogr. 2016; 14(4):139-145. DOI: 10.1007/s12574-016-0292-6. View

Boers-Doets C, Raber-Durlacher J, Treister N, Epstein J, Arends A, Wiersma D . Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013; 9(12):1883-92. DOI: 10.2217/fon.13.141. View

Kaeberlein M, Creevy K, Promislow D . The dog aging project: translational geroscience in companion animals. Mamm Genome. 2016; 27(7-8):279-88. PMC: 4936929. DOI: 10.1007/s00335-016-9638-7. View

Pitt J, Kaeberlein M . Why is aging conserved and what can we do about it?. PLoS Biol. 2015; 13(4):e1002131. PMC: 4414409. DOI: 10.1371/journal.pbio.1002131. View

Johnson S, Sangesland M, Kaeberlein M, Rabinovitch P . Modulating mTOR in aging and health. Interdiscip Top Gerontol. 2014; 40:107-27. DOI: 10.1159/000364974. View

10.

Wilkinson J, Burmeister L, Brooks S, Chan C, Friedline S, Harrison D . Rapamycin slows aging in mice. Aging Cell. 2012; 11(4):675-82. PMC: 3434687. DOI: 10.1111/j.1474-9726.2012.00832.x. View

11.

Alexandre J, Raymond E, Armand J . [Rapamycin and CCI-779]. Bull Cancer. 1999; 86(10):808-11. View

12.

Singh J, Evans J, Levy D, Larson M, Freed L, FULLER D . Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 83(6):897-902. DOI: 10.1016/s0002-9149(98)01064-9. View

13.

DETWEILER D, Patterson D . The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci. 1965; 127(1):481-516. DOI: 10.1111/j.1749-6632.1965.tb49421.x. View

14.

Fischer K, Gelfond J, Soto V, Han C, Someya S, Richardson A . Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life. PLoS One. 2015; 10(5):e0126644. PMC: 4433347. DOI: 10.1371/journal.pone.0126644. View

15.

Parikh J, Hollingsworth K, Wallace D, Blamire A, MacGowan G . Normal age-related changes in left ventricular function: Role of afterload and subendocardial dysfunction. Int J Cardiol. 2016; 223:306-312. PMC: 5073997. DOI: 10.1016/j.ijcard.2016.07.252. View

16.

Halloran J, Hussong S, Burbank R, Podlutskaya N, Fischer K, Sloane L . Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012; 223:102-13. PMC: 3454865. DOI: 10.1016/j.neuroscience.2012.06.054. View

17.

Kaeberlein M . mTOR Inhibition: From Aging to Autism and Beyond. Scientifica (Cairo). 2014; 2013:849186. PMC: 3860151. DOI: 10.1155/2013/849186. View

18.

Ross C, Salmon A, Strong R, Fernandez E, Javors M, Richardson A . Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY). 2015; 7(11):964-73. PMC: 4694066. DOI: 10.18632/aging.100843. View

19.

Neff M, Rine J . A fetching model organism. Cell. 2006; 124(2):229-31. DOI: 10.1016/j.cell.2006.01.008. View

20.

Bitto A, Ito T, Pineda V, LeTexier N, Huang H, Sutlief E . Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Elife. 2016; 5. PMC: 4996648. DOI: 10.7554/eLife.16351. View